» Authors » Angela Castela

Angela Castela

Explore the profile of Angela Castela including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 433
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Syed F, Ballew O, Lee C, Rana J, Krishnan P, Castela A, et al.
bioRxiv . 2024 May; PMID: 38766166
Tyrosine protein-kinase 2 (TYK2), a member of the Janus kinase family, mediates inflammatory signaling through multiple cytokines, including interferon-α (IFNα), interleukin (IL)-12, and IL-23. Missense mutations in TYK2 are associated...
2.
Coomans de Brachene A, Alvelos M, Szymczak F, Zimath P, Castela A, Marmontel de Souza B, et al.
Diabetologia . 2024 Feb; 67(5):908-927. PMID: 38409439
Aims/hypothesis: The proinflammatory cytokines IFN-α, IFN-γ, IL-1β and TNF-α may contribute to innate and adaptive immune responses during insulitis in type 1 diabetes and therefore represent attractive therapeutic targets to...
3.
Szymczak F, Cohen-Fultheim R, Thomaidou S, Coomans de Brachene A, Castela A, Colli M, et al.
Front Endocrinol (Lausanne) . 2022 Dec; 13:1058345. PMID: 36518246
Introduction: Enterovirus infection has long been suspected as a possible trigger for type 1 diabetes. Upon infection, viral double-stranded RNA (dsRNA) is recognized by membrane and cytosolic sensors that orchestrate...
4.
Coomans de Brachene A, Scoubeau C, Musuaya A, Costa-Junior J, Castela A, Carpentier J, et al.
Diabetologia . 2022 Nov; 66(3):450-460. PMID: 36401627
Aims/hypothesis: Diabetes is characterised by progressive loss of functional pancreatic beta cells. None of the therapeutic agents used to treat diabetes arrest this process; preventing beta cell loss remains a...
5.
Szymczak F, Alvelos M, Marin-Canas S, Castela A, Demine S, Colli M, et al.
Sci Adv . 2022 Sep; 8(37):eabn5732. PMID: 36103539
IFNα is a key regulator of the dialogue between pancreatic β cells and the immune system in early type 1 diabetes (T1D). IFNα up-regulates HLA class I expression in human...
6.
Alvelos M, Szymczak F, Castela A, Marin-Canas S, Marmontel de Souza B, Gkantounas I, et al.
Islets . 2021 Jul; 13(3-4):51-65. PMID: 34241569
Exposure of human pancreatic beta cells to pro-inflammatory cytokines or metabolic stressors is used to model events related to type 1 and type 2 diabetes, respectively. Quantitative real-time PCR is...
7.
Coomans de Brachene A, Castela A, Musuaya A, Marselli L, Marchetti P, Eizirik D
Auto Immun Highlights . 2021 Mar; 12(1):6. PMID: 33773604
Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by the progressive destruction of pancreatic beta cells. Interferon-α (IFNα), an antiviral cytokine, is expressed in the pancreatic islets in...
8.
Alvelos M, Bruggemann M, Sutandy F, Juan-Mateu J, Colli M, Busch A, et al.
Life Sci Alliance . 2020 Dec; 4(3). PMID: 33376132
In pancreatic β-cells, the expression of the splicing factor SRSF6 is regulated by GLIS3, a transcription factor encoded by a diabetes susceptibility gene. down-regulation promotes β-cell demise through splicing dysregulation...
9.
Coomans de Brachene A, Castela A, Op de Beeck A, Mirmira R, Marselli L, Marchetti P, et al.
Diabetes Obes Metab . 2020 Jun; 22(10):1827-1836. PMID: 32476252
Aim: Type 1 diabetes (T1D) is a chronic autoimmune disease leading to progressive loss of pancreatic beta cells. Interferon (IFN)-α plays a critical role in the crosstalk between pancreatic beta...
10.
Colli M, Ramos-Rodriguez M, Nakayasu E, Alvelos M, Lopes M, Hill J, et al.
Nat Commun . 2020 May; 11(1):2584. PMID: 32444635
Interferon-α (IFNα), a type I interferon, is expressed in the islets of type 1 diabetic individuals, and its expression and signaling are regulated by T1D genetic risk variants and viral...